That, I would say, is the biggest question regarding this company right now. I suppose that ultimately it starts with management's priorities. It seems that they are more concerned with the day to day operations of making this company a success then they are about garnering positive press and analyst coverage. Not to say that's all bad, as this might be a real value play in a sector that is mostly filled with hype and lack of real revenues and growth. Maybe it's just this niche of the biotech sector that also has something to do with it...everybody seems to be focusing on either cancer stocks or the fly by night H1N1 stuff. It's OK, as long as you know before getting in here, it may be a long long time if ever before this company trades at a value that you might expect. Although I do think that when we start hearing about Bepreve nasal, that might just be the event that takes this company over the top....but that is likely a year or two off still.